IONIS PHARMACEUTICALS INC (IONS) Stock Price, Quote, News and Overview
NASDAQ:IONS - Nasdaq - US4622221004 - Common Stock - Currency: USD
IONS Quote, Performance and Key Statistics
28.4
+0.05 (+0.18%)
The current stock price of IONS is 28.4 USD. In the past month the price decreased by -13.23%. In the past year, price decreased by -30.19%.
IONS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About IONS
Company Profile
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,069 full-time employees. The firm has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. The company has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Company Info
IONIS PHARMACEUTICALS INC
2855 Gazelle Court
Carlsbad CALIFORNIA 92010 US
CEO: Brett P. MONIA
Employees: 927
Company Website: https://www.ionis.com/
Investor Relations: https://ir.ionispharma.com
Phone: 17609319200
IONIS PHARMACEUTICALS INC / IONS FAQ
What is the stock price of IONIS PHARMACEUTICALS INC today?
The current stock price of IONS is 28.4 USD. The price increased by 0.18% in the last trading session.
What is the ticker symbol for IONIS PHARMACEUTICALS INC stock?
The exchange symbol of IONIS PHARMACEUTICALS INC is IONS and it is listed on the Nasdaq exchange.
On which exchange is IONS stock listed?
IONS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IONIS PHARMACEUTICALS INC stock?
31 analysts have analysed IONS and the average price target is 59.94 USD. This implies a price increase of 111.07% is expected in the next year compared to the current price of 28.4. Check the IONIS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IONIS PHARMACEUTICALS INC worth?
IONIS PHARMACEUTICALS INC (IONS) has a market capitalization of 4.51B USD. This makes IONS a Mid Cap stock.
How many employees does IONIS PHARMACEUTICALS INC have?
IONIS PHARMACEUTICALS INC (IONS) currently has 927 employees.
What are the support and resistance levels for IONIS PHARMACEUTICALS INC (IONS) stock?
IONIS PHARMACEUTICALS INC (IONS) has a resistance level at 28.41. Check the full technical report for a detailed analysis of IONS support and resistance levels.
Is IONIS PHARMACEUTICALS INC (IONS) expected to grow?
The Revenue of IONIS PHARMACEUTICALS INC (IONS) is expected to grow by 7.82% in the next year. Check the estimates tab for more information on the IONS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IONIS PHARMACEUTICALS INC (IONS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IONS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IONS, evaluating the profitability, health, valuation and growth aspects
- IONIS PHARMACEUTICALS INC (IONS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IONIS PHARMACEUTICALS INC (IONS) Sales and EPS estimates to see what analysts future expectations are.
- IONIS PHARMACEUTICALS INC (IONS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IONIS PHARMACEUTICALS INC (IONS) Insider and Institutional Ownership to learn about the owners and their transactions.
- IONIS PHARMACEUTICALS INC (IONS) Stock Chart to make your own analysis
- IONIS PHARMACEUTICALS INC (IONS) Latest news and press-releases to stay up to date.
Does IONIS PHARMACEUTICALS INC (IONS) stock pay dividends?
IONS does not pay a dividend.
When does IONIS PHARMACEUTICALS INC (IONS) report earnings?
IONIS PHARMACEUTICALS INC (IONS) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of IONIS PHARMACEUTICALS INC (IONS)?
IONIS PHARMACEUTICALS INC (IONS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.04).
What is the Short Interest ratio of IONIS PHARMACEUTICALS INC (IONS) stock?
The outstanding short interest for IONIS PHARMACEUTICALS INC (IONS) is 8.31% of its float. Check the ownership tab for more information on the IONS short interest.
IONS Technical Analysis
IONS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IONS. The financial health of IONS is average, but there are quite some concerns on its profitability.
IONS Financial Highlights
Over the last trailing twelve months IONS reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS decreased by -18.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.11% | ||
| ROE | -77.15% | ||
| Debt/Equity | 2.12 |
IONS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to IONS. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of -27.26% and a revenue growth 7.82% for IONS